U.S. markets close in 5 hours 54 minutes

BioVaxys Technology Corp. (BVAXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3258+0.0157 (+5.06%)
As of 9:51AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3101
BidN/A x N/A
AskN/A x N/A
Day's Range0.3000 - 0.3300
52 Week Range0.0459 - 0.6200
Avg. Volume357,881
Market Cap29.605M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0560
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BVAXF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: HCA Healthcare, Inc.HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2020, the firm owned and operated 185 hospitals, 121 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • PR Newswire

    BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine

    BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Office ("USPTO") a provisional patent application for its haptenized viral antigen vaccine platform to elicit a broad cross-reactive immune response against most or all sarbecoviruses, the family of Coronaviruses that includes SARS-CoV-2, which causes Covid-19.

  • PR Newswire

    BioVaxys Announces BVX-0320 Poster Presentation at ISIRV-WHO Virtual Conference

    BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that a poster highlighting its preclinical data on BVX-0320, the Company's SARS-CoV-2 vaccine candidate based on its haptenized viral protein technology, will be presented at a joint Virtual Congress of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) and the World Health Organization (WHO), which is being held October 19-21, 2021.

  • PR Newswire

    BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission

    BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has started its planned in vivo animal toxicology study of CoviDTH in parallel with the preparation of an IND submission. Under the terms of a March 2021 agreement, global contract research organization ("CRO") Inotiv, Inc. ("Inotiv") is evaluating the safety, tolerability, and toxicity of the purified recombinant SARS-CoV-2 s-protein that is a principal constituent of CoviDTH in an